The hydroxychloroquine debate: a therapeutic dilemma for general practitioners

Eur J Public Health. 2021 Apr 24;31(2):283-285. doi: 10.1093/eurpub/ckab002.

Abstract

France has been at the epicenter of the worldwide debate about hydroxychloroquine, as the main advocacy for its use to treat COVID-19 comes from a research unit led by Didier Raoult in Marseille. Among a national panel of 2940 general practitioners, we found that physicians in the areas most strongly affected by the epidemic or closest to the epicenter of the controversy reported that the hydroxychloroquine debate had made it difficult for them to deal with patients' treatment requests. Their adherence to official recommendations was also lower. It will be necessary to examine the conditions producing so strong a conflict.

MeSH terms

  • COVID-19 Drug Treatment*
  • COVID-19* / epidemiology
  • Female
  • France / epidemiology
  • General Practitioners* / psychology
  • General Practitioners* / statistics & numerical data
  • Guideline Adherence / statistics & numerical data
  • Humans
  • Hydroxychloroquine* / therapeutic use
  • Male
  • Middle Aged
  • Physician-Patient Relations
  • Practice Guidelines as Topic

Substances

  • Hydroxychloroquine